



Updates on Antiretroviral Use in PLWHA

Date: 2/25/2020

Time: 12:00 – 1:00 PM

Continuing Pharmacy Education Program
Clinical Pharmacy Associates, Inc. &
DC Department of Health
HIV/AIDS, Hepatitis, STD,
TD Administration

Who should attend: The program is designed for pharmacists in the DC HIV/AIDS Pharmacy Network and pharmacists in client organizations of CPA/MedNovations.

Needs Statement: Disease management of clients/patients with HIV/AIDS requires pharmacists and other healthcare providers to receive updates in healthcare delivery.

Statement of Goal: To equip the practicing pharmacist with current knowledge and understanding of topics integral to the care and safety of persons infected with HIV.

Activity Type: Knowledge

Objectives: After completing the program, participants should be able to:

- Explain the history of antiretroviral drug therapies in the USA
- Classify the list of current available FDA-approved antiretroviral (ART) drugs by class
- Identify recent FDA-approved ART drugs and their place in therapy
- Summarize the key guideline updates regarding ART drug therapy
- Explain highlights of recent safety-related drug labeling changes in HIV treatment
- Outline the 90-90-90-50 plan for the District of Columbia and the role of the DC ADAP

Faculty

Bamidele Kalejaiye, Pharm.D. BCPS,
Clinical Pharmacy Associates, Inc. 316
Talbott Avenue,
Laurel, MD 20707

Fee: N/A



® Howard University College of Pharmacy, (COP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. **This program meets ACPE criteria for one contact hour (0.1 CEU).** Credit will be awarded through the CPE Monitor, within 3–4 weeks of the seminar to those who successfully complete the program. Using the following URL: <https://hurxce.learningexpressce.com/index.cfm>, the evaluation form and a score $\geq 70\%$ correct on post-test questions will be required for successful completion. The ACPE Universal Program number assigned to this program is **0010-9999-20-003-L02-P**